Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax
Cabral-Miranda, G.; Heath, M.D.; Mohsen, M.O.; Gomes, A.C.; Engeroff, P.; Flaxman, A.; Leoratti, F.M.S.; El-Turabi, A.; Reyes-Sandoval, A.; Skinner, M.A.; Kramer, M.F.; Bachmann, M.F. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines 2017, 5, 10. https://doi.org/10.3390/vaccines5020010
Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines. 2017; 5(2):10. https://doi.org/10.3390/vaccines5020010
Chicago/Turabian StyleCabral-Miranda, Gustavo, Matthew D. Heath, Mona O. Mohsen, Ariane C. Gomes, Paul Engeroff, Amy Flaxman, Fabiana M.S. Leoratti, Aadil El-Turabi, Arturo Reyes-Sandoval, Murray A. Skinner, Matthias F. Kramer, and Martin F. Bachmann. 2017. "Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax" Vaccines 5, no. 2: 10. https://doi.org/10.3390/vaccines5020010